The role of [18F]FDG PET/CT in paraneoplastic autoimmune disorders: an umbrella review.

Details

Serval ID
serval:BIB_4307E0AEBAAC
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
The role of [18F]FDG PET/CT in paraneoplastic autoimmune disorders: an umbrella review.
Journal
The quarterly journal of nuclear medicine and molecular imaging
Author(s)
Muoio B., Albano D., Dondi F., Bertagna F., Annunziata S., Fiz F., Piccardo A., Sadeghi R., Treglia G.
ISSN
1827-1936 (Electronic)
ISSN-L
1824-4785
Publication state
Published
Issued date
09/2022
Peer-reviewed
Oui
Volume
66
Number
3
Pages
229-233
Language
english
Notes
Publication types: Journal Article ; Meta-Analysis
Publication Status: ppublish
Abstract
Paraneoplastic autoimmune disorders (PAD) are a group of autoimmune diseases associated with neoplasms. Several evidence-based articles (systematic reviews and meta-analyses) have reported data about the role of positron emission tomography (PET) and related hybrid modalities (e.g., PET/CT) using 2-deoxy-2-[18F]fluoro-D-glucose ([ <sup>18</sup> F]FDG) in patients with PAD. We performed an umbrella review of published systematic reviews and meta-analyses in this setting to provide an evidence-based summary and suggestions for further studies. Several databases were searched to find systematic reviews and meta-analysis on [ <sup>18</sup> F]FDG PET/CT in PAD. Evidence-based data support the use of [ <sup>18</sup> F]FDG PET/CT in patients with suspected PAD for investigating an underlying malignancy even if it is still unclear whether [ <sup>18</sup> F]FDG PET/CT should be performed after negative/inconclusive conventional imaging or as part of the initial workup of PAD.
Keywords
Autoimmune Diseases/diagnostic imaging, Fluorodeoxyglucose F18, Humans, Neoplasms, Positron Emission Tomography Computed Tomography, Positron-Emission Tomography/methods
Pubmed
Create date
31/05/2022 10:47
Last modification date
14/06/2023 6:56
Usage data